Currently Viewing:
Newsroom
Currently Reading
Review Finds Mixed Results for APMs and New Care Delivery Models in Cancer
September 23, 2018 – Laura Joszt
Researchers Identify New Cancer Cell That Is Key to Relapse in AML
September 23, 2018 – Laura Joszt
Embarrassment Contributes to Poor Asthma Treatment Adherence, Study Finds
September 22, 2018 – Alison Rodriguez
Researchers Struggle to Define Quality Indicators for Hip Fracture
September 22, 2018 – Allison Inserro
Researchers Assess Myofascial Trigger Points in Migraine and Tension-Type Headaches
September 22, 2018 – Alison Rodriguez
Bidens Celebrate Progress, Highlight Need for More at Biden Cancer Summit
September 21, 2018 – Jaime Rosenberg
Researchers Tout Behavioral Science to Increase Physical Activity in Patients With MS
September 21, 2018 – Jaime Rosenberg
PhRMA Tries to Use Opioid Bill to Shift Part D Costs to Medicare
September 21, 2018 – Mary Caffrey
More Data Necessary to Determine Best Treatment Option in Basal Cell Carcinoma
September 21, 2018 – Samantha DiGrande

New Opportunities and Challenges in Hepatitis C

Hepatitis C is an enormously common disease that is often initially asymptomatic. New drugs are very effective, but expensive, and there has been reluctance to cover these treatments. Authors that published research in the hepatitis C special issue present their findings.



Darius Lakdwalla, PhD, gave attendees a better understanding of "the dismal science of economics" as it relates to the HCV cures. Since hepatitis C is largely asymptomatic for a number of years, it takes a while for the benefit of treatment to accrue, he explained.

"If you compare people who are successfully treated, essentially cured with no viral load in their body, and compare them to other people with hepatitis C, who still are infected with the virus, over the first couple of years there's not a really big difference in death rates among those 2 populations," he explained.

It takes about 15 years or more to start to see a difference, Lakdawalla said. Unfortunately, many of the people infected with HCV are covered by private insurance or Medicaid, and this is an economic problem because neither of those entities cover people for very long.

"So think about this: we've got a disease where the cost of it manifests long into the future ... 10, 15 years down the road," he said. "But private payers typically are only covering people for about 3 or 4 years. So that creates a significant problem where the payer that has to bear the cost of paying for the treatment doesn't stick around long enough to see the benefits in the future."


 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!